International Medical News Group LLC

SHERPA: Unknown

People

  1. Lichtman
    Lichtman

Groups

  1. Department of Medicine (39)
  2. Solid Tumor Oncology Division (39)
  3. Gynecologic Medicine Service (38)
  4. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (1)
  5. GSK Faculty (1)
  6. Melanoma and Immunotherapeutics Service (1)
Search Within
Formats
  1. Journal Article (40)
Groups
  1. Department of Medicine (39)
  2. Solid Tumor Oncology Division (39)
  3. Gynecologic Medicine Service (38)
  4. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (1)
  5. GSK Faculty (1)
  6. Melanoma and Immunotherapeutics Service (1)
People
  1. Stuart Lichtman (38)
  2. Jedd Wolchok (1)
  3. Karyn Goodman (1)
  4. Paul Chapman (1)
Years
  1. 2015 (1)
  2. 2012 (1)
  3. 2011 (4)
  4. 2010 (4)
  5. 2007 (9)
  6. 2006 (9)

More Years

Publications
  1. The Oncology Report (40)

Results (40)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Front-line XELOXA regimen delays progression of metastatic colorectal cancer
    Journal Article

    Lichtman, S. M.
    The Oncology Report (2005)

    Fulltext@MSK | Save
  • Microsatellite instability status may aid in treatment decisions for colorectal cancer
    Journal Article

    Lichtman, S. M.
    The Oncology Report (2005)

    Fulltext@MSK | Save
  • Some colorectal cancer patients who have exhausted other options respond to cetuximab
    Journal Article

    Lichtman, S. M.
    The Oncology Report (2005)

    Fulltext@MSK | Save
  • Studies show improved survival with bevacizumab/FOLFOX4 for colorectal cancer
    Journal Article

    Lichtman, S. M.
    The Oncology Report (2005)

    Fulltext@MSK | Save
  • Adjuvant capecitabine at least equivalent to 5-FU/LV in colon cancer
    Journal Article

    Lichtman, S. M.
    The Oncology Report (2005)

    Fulltext@MSK | Save
  • Trial favors FLOX over 5-FU/LV for stage II, III colon cancer - Comment
    Journal Article

    Lichtman, S. M.
    The Oncology Report (2005)

    Fulltext@MSK | Save
  • FOLFOX4 matches irinotecan as second-line therapy for advanced CRC - Comment
    Journal Article

    Lichtman, S. M.
    The Oncology Report (2005)

    Fulltext@MSK | Save
  • Bevacizumab proves a useful adjunct in advanced colorectal cancer - Comment
    Journal Article

    Lichtman, S. M.
    The Oncology Report (2005)

    Fulltext@MSK | Save
  • Benefit of 5-FU and leucovorin in stage II and III colon cancer is durable - Comment
    Journal Article

    Lichtman, S. M.
    The Oncology Report (2005)

    Fulltext@MSK | Save
  • PETACC-3 evaluates role of irinotecan in the adjuvant treatment of colon cancer - Comment
    Journal Article

    Lichtman, S. M.
    The Oncology Report (2005)

    Fulltext@MSK | Save

    • International Medical News Group LLC – authorized name for: